Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy

Background and PurposeWe investigated the locoregional effect of trastuzumab, and determined whether patients with human epidermal growth factor receptor (HER)2-positive breast cancer (BC) treated with trastuzumab could achieve comparable efficacy to that of patients with HER2-negative BC.Materials...

Повний опис

Бібліографічні деталі

Автори:	Guang-Yi Sun, Hao Jing, Shu-Lian Wang, Yong-Wen Song, Jing Jin, Hui Fang, Yue-Ping Liu, Hua Ren, Yu Tang, Xu-Ran Zhao, Yu-Chun Song, Si-Ye Chen, Zhuan-Bo Yang, Bo Chen, Yuan Tang, Ning Li, Ning-Ning Lu, Shu-Nan Qi, Yong Yang, Ye-Xiong Li
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2021-01-01
Серія:	Frontiers in Oncology
Предмети:	breast cancer HER2 trastuzumab radiotherapy prognosis
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fonc.2020.605750/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!